Business Context and Reporting Period
Company: Innate Pharma SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: September 18, 2026
Reporting Period: The filing incorporates by reference the Half-Year Financial Report for the period January 1, 2025, to June 30, 2025 (Exhibit 99.2).
Principal Executive Office: Marseille, France
Key Financial Metrics
The provided text is a cover sheet and incorporation by reference document. It does not contain the actual financial data from the referenced Half-Year Financial Report (Exhibit 99.2). Consequently, the filing text does not provide clear values for:
- Revenue
- Profit or Net Income
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide specific data to compare against prior periods. Material changes in financial performance or position are not detailed in this excerpt.
Guidance, Outlook, and Risks
This document serves to incorporate the H1 2025 financial report into existing registration statements (Form F-3 and Form S-8). It does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies within the text provided.
Investor Verification Checklist
- Verify Exhibit 99.2: The actual financial numbers are located in the attached "H1 2025 Half-Year Financial Report" (Exhibit 99.2), which is not included in the input text.
- Check Registration Statements: Confirm the status of the Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031) into which this report is incorporated.
- Review Statutory Auditors' Report: Note that the Statutory Auditors' Review Report on page 49 of Exhibit 99.2 is explicitly excluded from the incorporation by reference.
- Confirm Date Discrepancy: Verify the reporting timeline, as the report date is September 2026, but the financial data covers the period ending June 30, 2025.